Semaglutide Market Faces Slump with ₹100 Crore Excess Stock

The explosive growth in India's obesity and weight-loss therapy market has hit a significant roadblock as sales of semaglutide treatments slowed down unexpectedly in May. After a period of rapid expansion fueled by generic entries, the industry is now grappling with a massive inventory overhang that could impact profitability.

The Sudden Slowdown in a High-Growth Market

The obesity therapy market, valued at approximately ₹2,000 crore, experienced a dramatic shift in momentum between April and May. In April, the market saw a massive surge, with value growth jumping 50% month-on-month and volumes increasing by 88%. This spike was largely driven by the influx of cheaper generic semaglutide brands from major pharmaceutical players like Sun Pharma, Dr. Reddy's, and Torrent following the drug's patent expiry on March 20.

However, the May data tells a different story. According to market research firm Pharmarack, month-on-month value growth decelerated to just 6%, while unit growth slowed to 12%. This sudden cooling off has left the supply chain struggling to balance the rapid influx of new products with actual consumer demand.

Inventory Overhang and Supply Chain Stagnation

The primary concern for industry stakeholders is the massive accumulation of unsold stock. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), reported that stockists and wholesalers are currently holding 50-60 days of GLP-1 (semaglutide) inventory. This is significantly higher than the standard industry norm of 30-45 days.

Industry estimates suggest that the value of this excess stock sitting in the trade channel is close to ₹100 crore. As a result, many channel partners have implemented a moratorium on fresh procurement from pharmaceutical manufacturers, opting to liquidate existing stocks before placing new orders. This pause in the procurement cycle could lead to a temporary period of stagnation for manufacturers.

Regulatory Impact and Market Resilience

While semaglutide faces inventory challenges, the broader GLP-1 receptor agonist market shows mixed signals. Eli Lilly’s Mounjaro (tirzepatide), another major player in the weight-loss segment, remained a leader, with sales increasing by 12% to reach ₹136 crore in May.

Industry executives suggest that the recent moderation in semaglutide sales may be partially attributed to stricter regulatory oversight. Following government advisories introduced in April, prescribing restrictions have been tightened, stipulating that GLP-1 therapies should only be prescribed by qualified specialists. This move aims to ensure clinical safety but has also impacted the velocity of prescriptions in the retail market.

Key Takeaways

  • Massive Inventory Glut: The semaglutide trade channel is currently saddled with approximately ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
  • Deceleration in Growth: After a massive 50% value surge in April, May saw month-on-month value growth plummet to just 6%.
  • Regulatory Headwinds: New guidelines requiring specialists to prescribe GLP-1 therapies are believed to be contributing to the slowdown in sales velocity.